EcoDrugPlus

Glucagon Receptor-Like

Ensembl ID : ENSSTUG00000004062
Gene Symbol: LOC115206008
2 Cross references
179 Possible Orthologues:

Glucagon-Like Peptide 2 Receptor

Ensembl ID : ENSSTUG00000016554
Gene Symbol: LOC115201282
2 Cross references
199 Possible Orthologues:

Glucocorticoid Receptor-Like

Ensembl ID : ENSSTUG00000012316
Gene Symbol: LOC115167519
3 Cross references
200 Possible Orthologues:

Glucocorticoid Receptor-Like

Ensembl ID : ENSSTUG00000011302
Gene Symbol: LOC115205684
3 Cross references
200 Possible Orthologues:

Glucokinase-Like

Ensembl ID : ENSSTUG00000028305
Gene Symbol: LOC115164221
3 Cross references
205 Possible Orthologues:

Glucokinase-Like

Ensembl ID : ENSSTUG00000026872
Gene Symbol: LOC115200421
3 Cross references
205 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSSTUG00000033340
Gene Symbol: GRIN2B
3 Cross references
245 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSSTUG00000004282
Gene Symbol: GRIN2B
3 Cross references
246 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2c

Ensembl ID : ENSSTUG00000045795
Gene Symbol: GRIN2C
3 Cross references
243 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2c

Ensembl ID : ENSSTUG00000002985
Gene Symbol: GRIN2C
3 Cross references
243 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2c

Ensembl ID : ENSSTUG00000014450
Gene Symbol: GRIN2C
3 Cross references
110 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2c

Ensembl ID : ENSSTUG00000008256
Gene Symbol: GRIN2C
3 Cross references
109 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).